Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 14/20 | 0.59 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | IGF1R | P08069 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL3431862 | 0.90 | PNMT (0.52) | PNMTTAAR1SIGMAR1IDO1CYP1A2 | |
| SCHEMBL9177318 | 0.86 | SIGMAR1 (0.62) | PNMTTAAR1SIGMAR1IDO1CYP1A2 | |
| SCHEMBL1448394 | 0.85 | SIGMAR1 (0.63) | PNMTTAAR1SIGMAR1IDO1CYP1A2 | |
| SCHEMBL11066232 | 0.83 | SIGMAR1 (0.61) | PNMTTAAR1SIGMAR1ALDH1A1TP53 | |
| SCHEMBL11136476 | 0.83 | AHR (0.56) | PNMTTAAR1SIGMAR1IDO1MAPT | |
| SCHEMBL22333700 | 0.83 | SIGMAR1 (0.61) | PNMTTAAR1SIGMAR1ALDH1A1TP53 | |
| SCHEMBL7637395 | 0.82 | CNR1 (0.45) | PNMTTAAR1SIGMAR1CYP1A2MEN1 | |
| SCHEMBL12045765 | 0.82 | ALOX5 (0.47) | PNMTTAAR1SIGMAR1CYP1A2MEN1 | |
| SCHEMBL8338503 | 0.82 | SIGMAR1 (0.47) | PNMTTAAR1SIGMAR1CYP1A2MEN1 | |
| SCHEMBL12841593 | 0.82 | SKP2 (0.46) | PNMTTAAR1SIGMAR1CYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299354-B1 | FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-22 | — | — | EP | claimed |
| EP-0767174-A1 | Novel aminoalkanephosphinic acids and their salts | CIBA-GEIGY AG (CH) | 1997-04-09 | — | — | EP | claimed |
| US-5376684-A | Aminobutyric acid antagonist; antiepileptic agent | CIBA-GEIGY CORPORATION (US) | 1994-12-27 | — | — | US | claimed |
| EP-0543780-A2 | Novel aminoalkanephosphinic acids and their salts | CIBA-GEIGY AG (CH) | 1993-05-26 | — | — | EP | claimed |
| EP-3863638-B1 | PHOSPHODIESTERASE INHIBITORS | UNIV NEBRASKA (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| WO-2023235548-A1 | SQUARAMIDE DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RESEARCH TRIANGLE INSTITUTE (US) | 2023-12-07 | — | — | WO | disclosed |
| US-11529347-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-04-28 | — | — | US | disclosed |
| US-11225480-B2 | Malic enzyme inhibitors | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-01-18 | — | — | US | disclosed |
| US-11203572-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-11180499-B2 | Phosphodiesterase inhibitors | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2021-11-23 | — | — | US | disclosed |
| EP-1162194-A1 | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use | Aventis Pharma Deutschland GmbH (DE) | 2001-12-12 | — | — | EP | disclosed |
| US-6288079-B1 | MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS; NERVOUS SYSTEM, PSYCHOLOGICAL, EATING, SLEEP, AND BRAIN DISORDERS; ALZHEIMER*S AND PARKINSON*S DISEASE; TESOFENSINE (2-ethoxymethyl-3-(3,4-dichlorophenyl)-tropane) | NEUROSEARCH A/S (DK) | 2001-09-11 | — | — | US | disclosed |
| EP-0885220-A1 | TROPANE-DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997030997-A1 | TROPANE-DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 1997-08-28 | — | — | WO | disclosed |
| EP-0767174-A1 | Novel aminoalkanephosphinic acids and their salts | CIBA-GEIGY AG (CH) | 1997-04-09 | — | — | EP | disclosed |
| US-5500418-A | ANTIEPILEPTIC | CIBA-GEIGY CORPORATION (US) | 1996-03-19 | — | — | US | disclosed |
| US-5376684-A | Aminobutyric acid antagonist; antiepileptic agent | CIBA-GEIGY CORPORATION (US) | 1994-12-27 | — | — | US | disclosed |
| EP-0543780-A2 | Novel aminoalkanephosphinic acids and their salts | CIBA-GEIGY AG (CH) | 1993-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | PNMT 4052/4885TAAR1 4878/4885SIGMAR1 4503/4885 |
| US-11225480-B2 | Malic enzyme inhibitors | ME1, RNASE1, ME2 | PNMT 3844/4885TAAR1 3983/4885SIGMAR1 3067/4885 |
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | PNMT 1863/4885TAAR1 4603/4885SIGMAR1 4820/4885 |
| US-11529347-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPN21, PTPN22, PTPN5 | PNMT 4845/4885TAAR1 4139/4885SIGMAR1 4155/4885 |
| US-11203572-B2 | Substituted benzamides and methods of use thereof | BRIX1, RDX, RRM1 | PNMT 1985/4885TAAR1 2806/4885SIGMAR1 537/4885 |
| US-11180499-B2 | Phosphodiesterase inhibitors | PDE4A, PDE4B, PDE4C | PNMT 131/4885TAAR1 491/4885SIGMAR1 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.